Type 1 Diabetes prevention trial with the antigen-specific immunotherapy Diamyd® approved to start

The Swedish Medical Products Agency and the Ethical Review Authority have approved the start of DiaPrecise, an open-label prevention trial with the antigen-specific immunotherapy Diamyd[®]. The trial will evaluate the safety, feasibility and immune response of intralymphatic injections of Diamyd[®] in children at risk of Type 1 Diabetes, who also carry the genetically defined haplotype HLA DR3-DQ2. DiaPrecise is part of the ASSET program (AI for the Sustainable Prevention of Autoimmunity in Society), coordinated by Diamyd Medical and funded by Sweden’s Innovation Agency VINNOVA.“Preventing